Reach Us +44-1904-929220
From Bench To Bedside | 3650

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

From bench to bedside

2nd World Congress on Biomarkers & Clinical Research

Gargi D Basu

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

A major goal of cancer research is to test cancer tissue at the molecular level and make therapeutic predictions. Personalized medicine is a rapidly advancing aspect of health care that is based on each person?s unique clinical, genetic, genomic and environmental information. It depends on providing a comprehensive understanding of personalized medicine from scientifi c discovery at the laboratory bench to the implementation of these novel pathways of understanding human biology at the bedside. One of the most widely used molecular profi ling services with the most accepted methods is Caris Target Now. Th e goal of Target Now is to identify clinically relevant and patient specifi c biomarkers from the patients? tumor and help inform more eff ective and targeted treatment options. A variety of tests are performed on each tumor sample including immunohistochemistry, fl uorescent in situ hybridization, microarray analysis and DNA sequencing. Th e profi led biomarkers are then reported out with drug associations. In a pilot study, treatment recommended by Target Now molecular profi ling has been shown to increase progression free survival among some patients. Caris Target Now combines comprehensive molecular pathology and tumor profi ling with an exhaustive evidence- based review of the latest clinical literature on biomarkers and their correlation to potential drug response. Th is provides treating physicians with the information needed to personalize cancer treatment. Some of the Target Now tests performed on common tumor types and their association with therapy will be discussed in detail
Gargi Basu had completed her Ph.D from All India Institute of Medical Sciences in 1999 and then joined Mayo Clinic for postdoctoral studies. She is currently working at Caris Life Sciences in the Biomarker Evidence Team as a scientist. She has published over 25 papers in reputed journals and her work has appeared in Dr. Robert Weinberg?s book on ?The Biology of Cancer? and also on the cover of AACR journal. Her work on breast cancer has been featured on Breast Cancer Net News Release and on AACR Press Release.
Relevant Topics